Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Domenyuk, V; Gatalica, Z; Santhanam, R; Wei, X; Stark, A; Kennedy, P; Toussaint, B; Levenberg, S; Wang, J; Xiao, N; Greil, R; Rinnerthaler, G; Gampenrieder, SP; Heimberger, AB; Berry, DA; Barker, A; Quackenbush, J; Marshall, JL; Poste, G; Vacirca, JL; Vidal, GA; Schwartzberg, LS; Halbert, DD; Voss, A; Magee, D; Miglarese, MR; Famulok, M; Mayer, G; Spetzler, D.
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Nat Commun. 2018; 9(1): 1219
Doi: 10.1038/s41467-018-03631-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Rinnerthaler Gabriel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Assessing the phenotypic diversity underlying tumour progression requires the identification of variations in the respective molecular interaction networks. Here we report proof-of-concept for a platform called poly-ligand profiling (PLP) that surveys these system states and distinguishes breast cancer patients who did or did not derive benefit from trastuzumab. We perform tissue-SELEX on breast cancer specimens to enrich single-stranded DNA (ssDNA) libraries that preferentially interact with molecular components associated with the two clinical phenotypes. Testing of independent sample sets verifies the ability of PLP to classify trastuzumab-treated patients according to their clinical outcomes with ROC-AUC of 0.78. Standard HER2 testing of the same patients gives a ROC-AUC of 0.47. Kaplan-Meier analysis reveals a median increase in benefit from trastuzumab-containing treatments of 300 days for PLP-positive compared to PLP-negative patients. If prospectively validated, PLP may increase success rates in precision oncology and clinical trials, thus improving both patient care and drug development.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Antineoplastic Agents, Immunological - therapeutic use
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Area Under Curve - administration & dosage
- Biomarkers, Tumor - analysis
- Breast Neoplasms - drug therapy, genetics
- DNA, Single-Stranded - analysis
- Disease Progression - administration & dosage
- Disease-Free Survival - administration & dosage
- Female - administration & dosage
- Gene Expression Regulation, Neoplastic - administration & dosage
- Humans - administration & dosage
- Kaplan-Meier Estimate - administration & dosage
- Ligands - administration & dosage
- Middle Aged - administration & dosage
- Phenotype - administration & dosage
- Precision Medicine - administration & dosage
- SELEX Aptamer Technique - administration & dosage
- Sequence Analysis, DNA - administration & dosage
- Trastuzumab - therapeutic use
- Treatment Outcome - administration & dosage